PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc Splicing Deep Dive Transcript

Jul 24, 2020 / 02:00PM GMT
Release Date Price: €40 (-0.50%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the PTC Splicing Deep Dive Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Alex Kane, Executive Director of Investor Relations. Thank you. Please go ahead, sir.

Alex Kane
PTC Therapeutics, Inc. - IR Officer

Thank you, and good morning, everyone. Happy Friday. Thank you for joining us today for this second webinar in our deep dive series focused on the splicing platform. With me on today's call is our Chief Executive Officer, Stuart Peltz; and our Chief Scientific Officer, Mark Pykett. We're also pleased to have on the call 3 key members of the research team who have 30-plus years of combined experience at PTC, largely focused on RNA biology. With us on the call is Nikolai Naryshkin, our VP of External Innovation; Chris Trotta, our VP of Biology; and Matt Woll, our VP of Chemistry.

Before we start, let me remind you that today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot